Orthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix International Provides Fourth

Orthofix International

Provides Fourth Quarter and Full-Year 2013 Results

Announces Strategic Plan to Further Drive Profitable Growth

Creates New Strategic Business Unit Structure to Enhance Focus and Provide Greater Transparency

Company to Host Conference Call at 8:30 AM ET

LEWISVILLE, TX. March 27, 2014 Orthofix International N.V., (NASDAQ:OFIX) today reported results for the fourth quarter and full year ended

Dec. 31, 2013. For full-year 2013, net sales were $400.5 million, decreasing 11 percent on a reported basis and constant currency basis from $447.6 million in the prior year. For the fourth quarter 2013, net sales were $106.1 million, decreasing 10

percent on a reported and constant currency basis from $117.4 million in the fourth quarter of the prior year.

Commenting on the Company s financial

results, Orthofix President and Chief Executive Officer Brad Mason said, Orthofix is clearly a company in transition. Over the course of 2013, we made a lot of headway in many areas, behind the scenes. We undertook a bottoms-up analysis of

every aspect of the Company, which led us to implement numerous changes in people and business processes and to renew our focus on growth strategies.

Mr. Mason continued, This past year has been challenging and the 2013 financial performance is not reflective of where the Company should be

operating. However, we expect stronger financial results in 2014 and are laying the groundwork for further growth and profitability in 2015 and 2016. We are confident that the changes we have made and the initiatives currently underway are resulting

in a stronger Company driven by integrity and with a renewed focus on delivering results that meet or exceed our stakeholders expectations.

Strategic Plan to Improve Profitability and Performance

In 2013, Orthofix redefined its business segments to allow each business unit to focus on distinct attributes and opportunities that maximize their potential,

as well as provide greater internal and external transparency. These strategic business units (SBUs) are: BioStim, Biologics, Extremity Fixation and Spine Fixation. To provide greater external transparency into these SBUs, the Company will provide

SBU-specific net sales and net margin, the latter of which is the measure of profit that best reflects the contribution margin of each of the SBUs. The Company calculates net margin as gross profit less sales and marketing expenses.

Furthermore, the Company has substantially enhanced its leadership team worldwide, including appointing a new Chairman of the Board and two additional highly

qualified Board members. In addition to new leadership, the Company is implementing a number of key initiatives to strengthen its foundation and drive profitable growth. In addition to corporate initiatives, each SBU has developed and is executing

individual key strategies, which will be discussed on the Company s earnings call later today.

For full-year 2013, sales were $147.9 million, a

20 percent decrease on a constant currency basis over 2012. This decrease was primarily due to a decline in volume relating to turnover of spine and orthopedic distributors, and a one-time deferral of third-party payor revenue due to a change of

methodology to our billing process.

Biologics sales were $53.8 million for the full-year 2013, which increased slightly from $53.7 million for the full-year 2012. Total tissue usage for the full-year 2013 increased 5 percent compared to 2012, but was offset by a change in our

marketing service fee from Musculoskeletal Transplant Foundation (MTF) from 70 to 65 percent in April 2013, which occurred at the time of our Trinity Elite new product launch.

Full-year 2013 sales of Extremity

Fixation products were $103.4 million, a 7 percent constant currency decline compared to 2012 sales. This decline was predominantly the result of deterioration of sales in Brazil, as well as the negative impact of transitioning to sell-through

revenue recognition for international distributors beginning on April 1, 2013.

Full-year 2013 sales were $95.5 million, a 2 percent decrease on a constant currency basis compared to the prior year. This decrease was primarily due to a 6

percent decrease in our average selling prices due to price discounting, which was somewhat offset by increased international sales.

Full-year 2013 operating income from continuing operations was a loss of $5.1 million compared to income of $76.6 million in the

prior year. Full-year 2013 and 2012 operating income included certain specified items detailed below, including a $19.2 million non-cash charge related to an impairment of goodwill and $12.9 million of costs related to the Company s accounting

review and restatement. When excluding these and the other specified items detailed below, adjusted operating income in full-year 2013 was $34.2 million compared to $84.0 million in full-year 2012. Full-year 2013 net income from continuing

operations was a loss of $15.7 million compared to income of $45.1 million in the prior year. Full-year 2013 and 2012 net income also included the specified items detailed below. When excluding these items, adjusted net income from continuing

operations for the full-year 2013 was $14.2 million compared to $49.7 million in full-year 2012.

Orthofix will host a conference call to discuss fourth quarter and full-year 2013 results today, Thursday, March 27, 2014 at 8:30 a.m. EST (7:30 a.m.

CST). Interested parties may access the conference call by dialing (888) 267-2845 in the U.S. and (973) 413-6102 outside the U.S., and entering the conference ID 38220. A replay of the call will be available for two weeks by dialing

(800) 332-6854 in the U.S. and (973) 528-0005 outside the U.S., and entering the conference ID 38220. A webcast of the conference call may be accessed by going to the Company s website at www.orthofix.com, by clicking on the

Investors link and then the Events and Presentations page.

Orthofix International N.V. is a diversified, global medical device company focused on improving patients lives by providing superior reconstructive and

regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville TX, the Company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely

distributed via the Company s sales representatives, stocking distributors and its subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as the Musculoskeletal

Transplant Foundation, the Orthopedic Research and Education Foundation and the Texas Scottish Rite Hospital for Children. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains

certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of

operations and businesses of Orthofix and its subsidiaries and are based on management s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those

contemplated by the forward-looking statements.

The forward-looking statements in this release do not constitute guarantees or promises of future

performance. Factors that could cause or contribute to such differences may include, but are not limited to: risks relating to the Audit Committee review and financial restatement described herein and related legal proceedings (including potential

action by the Division of Enforcement of the SEC and pending securities class action litigation); the Company s review of allegations of improper payments involving the Company s Brazil-based subsidiary; the Company s non-compliance

with certain NASDAQ Stock Market listing rules, and related pending hearings proceedings in connection therewith; the expected sales of the Company s products, including recently launched products; unanticipated expenditures; changing

relationships with customers, suppliers, strategic partners and lenders; changes to and the interpretation of governmental regulations; the resolution of pending litigation matters (including the Company s indemnification obligations with

respect to certain product liability claims against, and the government investigation of, the Company s former sports medicine global business unit, as further described in the Legal Proceedings section of the Company s

Amendment No. 1 to Annual Report on Form 10-K/A for the year ended December 31, 2012 (the Form 10-K/A ), and other subsequent periodic reports filed by the Company with the SEC); the Company s ongoing compliance obligations

under a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services (and related terms of probation), and a deferred prosecution agreement with the U.S. Department of Justice and a Consent Decree

with the SEC; risks relating to the protection of intellectual property; changes to the reimbursement policies of third parties; the impact of competitive products; changes to the competitive environment, the acceptance of new products in the

market, conditions of the orthopedic industry, credit markets and the economy; corporate development and market development activities, including acquisitions or divestitures, unexpected costs or operating unit performance related to recent

acquisitions; and other risks described in Item 1A under the heading Risk Factors in the Form 10-K/A, as well as in other subsequent periodic reports filed by the Company with the SEC. Existing and prospective investors are

cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release.

The following tables are summaries of fourth quarter and full-year 2013 sales reconciled to constant currency

sales growth. Amounts shown are in millions and reflect unaudited figures.

External net sales by Strategic Business Unit

Note: Some calculations may be impacted by rounding.

External net sales by Strategic Business Unit

Note: Some calculations may be impacted by rounding.

The following tables are summaries of fourth quarter and full-year 2013 net margin calculations by global

business unit. Amounts shown are in millions and reflect unaudited figures.

The following table reconciles operating income from continuing operations to adjusted operating income from continuing

operations for the fourth quarters and full-years ended December 31, 2013 and 2012:

Fourth Quarter Adjusted Operating Income from Continuing

Note: Some calculations may be impacted by rounding. Please refer to the Non-GAAP Performance measure section at the end of

this press release for more information about the specified items listed above.

Full Year Adjusted Operating Income from Continuing Operations

Note: Some calculations may be impacted by rounding. Please refer to the Non-GAAP Performance measure section at the end of

this press release for more information about the specified items listed above.

The following tables reconcile reported net income from continuing operations and net income from continuing

operations per diluted share to adjusted net income from continuing operations and adjusted net income from continuing operations per diluted share for the quarters ended Dec. 31, 2013 and 2012, and for the full-years ended December 31, 2013

Fourth Quarter Adjusted Net Income from Continuing Operations

Note: Some calculations may be impacted by rounding. Please refer to the Non-GAAP Performance Measure section at the end of

this press release for more information about the specified items listed above.

Full Year Adjusted Net Income from Continuing Operations

Note: Some calculations may be impacted by rounding.

Please refer to the Non-GAAP Performance Measure section at the end of this press release for more information about the specified items listed above.

The following table reconciles reported net cash provided by operating activities to adjusted free cash flow

for the full-years ended December 31, 2013 and 2012:

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, U.S. Dollars, in thousands)